Global

Unpopular Wall Street equities like Clorox and Campbell's gain momentum as artificial intelligence rally slows

Originally reported by CNBC Global as: From trash to treasure: Most hated stocks are winning as AI bull market rolls over

21 Nov 2026, 6:40 pm IST · Xecute.finance News Desk

The crisp read

Unpopular equities on Wall Street such as Clorox, Boston Beer, and Campbell's are positioned to succeed as the artificial intelligence trade loses momentum. This shift highlights a broader rotation away from technology leaders toward out-of-favor consumer names. Investors are reassessing portfolios as market dynamics evolve.

Deep dive – the full story

Several equities that are unpopular on Wall Street, including Clorox, Boston Beer, and Campbell's, are poised to be winners as the artificial intelligence trade loses steam. The rotation away from high-flying technology sectors reflects changing market sentiments and investor appetite for defensive or overlooked assets. In financial markets, sector rotation occurs when capital moves from one industry group to another in response to macroeconomic shifts, valuation concerns, or changing growth expectations.

Historically, when momentum slows in dominant growth sectors like artificial intelligence, capital frequently migrates toward consumer defensive or neglected equities to mitigate portfolio volatility and capture undervalued opportunities. Portfolio managers and financial advisors should review asset allocations to balance high-growth technology exposure with these emerging value opportunities.

Keep track of broader market indices and sector performance metrics to time portfolio rebalancing effectively. Bottom line: Monitoring shifts in market leadership protects capital from sudden corrections in overextended sectors.

Source: cnbc.com

This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.

More from the Xecute news desk

Reading the static edition.

The live app adds Ask Xecute, deadline trackers, the daily quiz and one-tap deep dives.

Open this story in the Xecute app →